Neurology®
The most widely read and highly cited peer-reviewed Neurology journal
Quick Search
Advanced Search
Published online before print December 28, 2005, doi:10.1212/01.wnl.0000195887.63124.dc)
This Article
Right arrow Figures Only
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow CME: Take the course for this article:
 Volume 66, Number 3, February 14, 2006
Right arrow Data Supplement
Right arrow All Versions of this Article:
01.wnl.0000195887.63124.dcv1
66/3/436    most recent
Right arrow Correspondence:
Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when Correspondence are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Göngora-Rivera, F.
Right arrow Articles by Santos-Zambrano, J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Göngora-Rivera, F.
Right arrow Articles by Santos-Zambrano, J.
Related Collections
Right arrow Parasitic infections
Right arrow All Clinical trials
Right arrow Clinical trials Randomized controlled (CONSORT agreement)
NEUROLOGY 2006;66:436-438
© 2006 American Academy of Neurology
Brief Communications

Albendazole trial at 15 or 30 mg/kg/day for subarachnoid and intraventricular cysticercosis

F. Göngora-Rivera, MD, J. L. Soto-Hernández, MD, D. González Esquivel, MS, H. J. Cook, PhD, C. Márquez-Caraveo, MD, R. Hernández Dávila, MD and J. Santos-Zambrano, MD

From the Department of Neurology (F.R-G., C.M.-C., R.H.D., J.S.-Z.), Department of Infectious Diseases (J.L.S.-H.), and Neuropharmacology Laboratory (D.G.E., H.J.C.), Instituto Nacional de Neurología y Neurocirugía Manuel Velasco Suárez, Mexico City, Mexico.

Address correspondence and reprint requests to Dr. José Luis Soto-Hernández, Department of Infectious Disease, Instituto Nacional de Neurología y Neurocirugía Manuel Velasco Suárez, Insurgentes Sur 3877, Tlalpan 14269, D.F., Mexico City, Mexico; e-mail: joseluis_sotohernandez{at}yahoo.com

Thirty-six patients with subarachnoid and intraventricular cysticercosis were randomly assigned to receive albendazole at 15 or 30 mg/kg/day plus dexamethasone for 8 days. Results favored a higher dose, with larger cyst reduction on MRI at 90 and 180 days and higher albendazole sulfoxide levels in plasma. An albendazole course at 30 mg/kg/day combined with corticosteroids is safe and more effective than the usual dose. A single treatment was insufficient in intraventricular and giant cysts.

Additional material related to this article can be found on the Neurology Web site. Go to www.neurology.org and scroll down the Table of Contents for the February 14 issue to find the title link for this article.

This article was previously published in electronic format as an Expedited E-Pub on December 28, 2005, atwww.neurology.org.

Disclosure: The authors report no conflicts of interest.

Received May 16, 2005. Accepted in final form October 27, 2005.




This article has been cited by other articles:


Home page
 NeurologyHome page
F. Gongora-Rivera, J. Luis Soto-Hernandez, P. Guevara, and J. Sotelo-Morales
IN NEUROCYSTICERCOSIS, CSF CYTOKINES CORRELATE WITH CEREBRAL BLOOD FLOW VELOCITIES
Neurology, September 30, 2008; 71(14): 1119 - 1122.
[Full Text] [PDF]

Home page
 J. Neurol. Neurosurg. PsychiatryHome page
A Fleury, M Hernandez, M Avila, G Cardenas, R J Bobes, M Huerta, G Fragoso, L Uribe-Campero, L J S Harrison, R M E Parkhouse, et al.
Detection of HP10 antigen in serum for diagnosis and follow-up of subarachnoidal and intraventricular human neurocysticercosis
J. Neurol. Neurosurg. Psychiatry, September 1, 2007; 78(9): 970 - 974.
[Abstract] [Full Text] [PDF]